이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

H. Lundbeck 대차 대조표 상태

재무 상태 기준 확인 5/6

H. Lundbeck 의 총 주주 지분은 DKK22.4B 이고 총 부채는 DKK3.7B, 이는 부채 대 자기자본 비율을 16.6% 로 가져옵니다. 총자산과 총부채는 각각 DKK37.9B 및 DKK15.4B 입니다. H. Lundbeck 의 EBIT는 DKK3.3B 이며 이자보상배율은 -23 입니다. DKK5.1B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

16.6%

부채 비율

DKK 3.72b

부채

이자 보상 비율	-23x
현금	DKK 5.11b
주식	DKK 22.44b
총 부채	DKK 15.42b
총 자산	DKK 37.85b

최근 재무 상태 업데이트

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05

Recent updates

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

재무 상태 분석

단기부채: HLUN B 의 단기 자산 ( DKK13.8B )이 단기 부채( DKK7.9B ).

장기 부채: HLUN B 의 단기 자산( DKK13.8B )이 장기 부채( DKK7.5B ).

부채 대 자본 내역 및 분석

부채 수준: HLUN B 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: HLUN B 의 부채 대 자기자본 비율은 지난 5년간 4% 에서 16.6% 로 증가했습니다.

부채 범위: HLUN B 의 부채는 영업 현금 흐름 ( 125.5% )에 의해 잘 충당되었습니다.

이자 보장: HLUN B 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.

H. Lundbeck 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Recent updates

Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기